CTSO
Cytosorbents Corporation
NASDAQ · USHealthcareMedical - Devices
$0.38+5.58%
Price as of Jul 20, 2026
CTSO profitability
Cytosorbents Corporation profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 71.0%
- EBITDA margin
- -20.9%
- EBIT margin
- -36.0%
- Net margin
- -31.9%
- Free cash flow margin
- -27.4%
Returns
- Return on equity
- -540.1%
- Return on assets
- -29.2%
- Return on invested capital
- -63.3%
- Asset turnover
- 0.88x
Cash efficiency
- Cash from operations
- -$10.1M
- Cash per share
- $0.08
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.